60 EXTENDED CC-486 (ORAL AZACITIDINE) DOSING IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS), ACUTE MYELOID LEUKEMIA (AML), OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML): SAFETY, TOLERABILITY, AND RESPONSE
2019 ◽
Vol 19
(5)
◽
pp. 264-274.e4
◽
2010 ◽
Vol 28
(15_suppl)
◽
pp. TPS282-TPS282
2016 ◽
Vol 209
(7-8)
◽
pp. 313-320
◽
2020 ◽
Vol 20
◽
pp. S191-S192
2016 ◽
Vol 58
(2)
◽
pp. 298-307
◽